Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

5.520 -0.150 (-2.65%)
Streaming Delayed Price Updated: 9:55 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care 
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET 
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Inc. (NASDAQ: IMMX) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
What's Going On With Cancer-Focused Immix Biopharma Stock Today? ↗
Immix Biopharma Inc (NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
The 3 Best Speculative Stocks to Buy Now: September 2023 ↗
These best speculative stocks are the ones to buy in the long term for strong returns on your investment portfolio. 
Via InvestorPlace
News headline image
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory Multiple Myeloma will be presented in Athens September 27-30, 2023 
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.